. 2019 Mar 6;145(4):1001–1012. doi: 10.1007/s00432-019-02854-x

Table 2.

Patient characteristics by randomization arm

Total patients	Arm ASP-5000	Arm ASP-10000	р
Total patients	n = 334	n = 354	р
Gender
Boys	181	192	0.949
Girls	153	162	0.949
Age (years)
≥ 1–< 5	161	189	0.370
≥ 5–<10	93	92
≥ 10	80	73
Initial WBC count
< 10,000/µl	210	227	0.271
≥ 10,000–< 30,000/µl	102	94
≥ 30,000–< 50,000/µl	22	33
Spleen enlargement below left costal margin (cm)
< 4	258	256	0.162
≥ 4	76	98	0.162
Genetics^a
t(12;21)	29	24	0.491
Response to treatment on day 8^b
< 1000 leukemic blasts/µl PB	318	331	0.473
≥ 1000 leukemic blasts/µl PB	9	14	0.473
Response to treatment on day 15^c
< 10% leukemic blasts in BM	272	285	0.790
≥ 10–< 25% leukemic blasts in BM	40	39
≥ 25% leukemic blasts in BM	19	24
Induction therapy
Dexamethasone 6 mg/m²	168	176	0.874
Methylprednisolone 60 mg/m²	163	177	0.874

ASP asparaginase, BM bone marrow, IM intramuscular, PB peripheral blood, WBC white blood cell count

^aInvestigation of relevant translocations performed in 506 patients (n = 251 in the arm ASP-5000, n = 255 in the arm ASP-10000)

^bTreatment response on day 8 was documented for 672 patients (327 patients in the arm ASP-5000, 345 patients in the arm ASP-10000)

^cTreatment response on day 15 was documented for 679 patients (331 patients in the arm ASP-5000, 348 patients in the arm ASP-10000)